BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL. DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res 2015;21:925-33. [PMID: 25480831 DOI: 10.1158/1078-0432.CCR-14-0842] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Yildiz G. Integrated multi-omics data analysis identifying novel drug sensitivity-associated molecular targets of hepatocellular carcinoma cells. Oncol Lett 2018;16:113-22. [PMID: 29930714 DOI: 10.3892/ol.2018.8634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Lan T, Zhao Z, Qu Y, Zhang M, Wang H, Zhang Z, Zhou W, Fan X, Yu C, Zhan Q, Song Y. Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling. Oncotarget 2016;7:55555-71. [PMID: 27487130 DOI: 10.18632/oncotarget.10864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Asleh K, Riaz N, Cheng AS, Gao D, Leung SCY, Anurag M, Nielsen TO. Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. NPJ Breast Cancer 2021;7:114. [PMID: 34504086 DOI: 10.1038/s41523-021-00320-x] [Reference Citation Analysis]
4 Nickoloff JA, Taylor L, Sharma N, Kato TA. Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy. Cancer Drug Resist 2021;4:244-63. [PMID: 34337349 DOI: 10.20517/cdr.2020.89] [Reference Citation Analysis]
5 Choi C, Son A, Lee GH, Shin SW, Park S, Ahn SH, Chung Y, Yu JI, Park HC. Targeting DNA-dependent protein kinase sensitizes hepatocellular carcinoma cells to proton beam irradiation through apoptosis induction. PLoS One 2019;14:e0218049. [PMID: 31194786 DOI: 10.1371/journal.pone.0218049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Zhou H, Zhu P, Wang J, Toan S, Ren J. DNA-PKcs promotes alcohol-related liver disease by activating Drp1-related mitochondrial fission and repressing FUNDC1-required mitophagy. Signal Transduct Target Ther. 2019;4:56. [PMID: 31839999 DOI: 10.1038/s41392-019-0094-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
7 Barbosa-silva A, Magalhães M, Da Silva GF, Da Silva FAB, Carneiro FRG, Carels N. A Data Science Approach for the Identification of Molecular Signatures of Aggressive Cancers. Cancers 2022;14:2325. [DOI: 10.3390/cancers14092325] [Reference Citation Analysis]
8 Dungl DA, Maginn EN, Stronach EA. Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy. Front Oncol 2015;5:240. [PMID: 26579492 DOI: 10.3389/fonc.2015.00240] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Myers SH, Ortega JA, Cavalli A. Synthetic Lethality through the Lens of Medicinal Chemistry. J Med Chem 2020;63:14151-83. [PMID: 33135887 DOI: 10.1021/acs.jmedchem.0c00766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mohiuddin IS, Kang MH. DNA-PK as an Emerging Therapeutic Target in Cancer. Front Oncol 2019;9:635. [PMID: 31380275 DOI: 10.3389/fonc.2019.00635] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 18.3] [Reference Citation Analysis]
11 Conconi D, Redaelli S, Lissoni AA, Cilibrasi C, Perego P, Gautiero E, Sala E, Paderno M, Dalprà L, Landoni F, Lavitrano M, Roversi G, Bentivegna A. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas. Int J Mol Sci 2021;22:1580. [PMID: 33557274 DOI: 10.3390/ijms22041580] [Reference Citation Analysis]
12 Wang L, Zhang Z, Li Y, Wan Y, Xing B. Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. Aging (Albany NY) 2020;13:2480-505. [PMID: 33411682 DOI: 10.18632/aging.202281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Yılmaz Y, Güneş A, Topel H, Atabey N. Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. J Gastrointest Cancer 2017;48:225-37. [PMID: 28819741 DOI: 10.1007/s12029-017-9958-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Yang S, Wang XQ. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance. BMC Cancer 2017;17:344. [PMID: 28526069 DOI: 10.1186/s12885-017-3345-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
15 Hafsi H, Dillon MT, Barker HE, Kyula JN, Schick U, Paget JT, Smith HG, Pedersen M, McLaughlin M, Harrington KJ. Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status. Front Oncol 2018;8:245. [PMID: 30057890 DOI: 10.3389/fonc.2018.00245] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
16 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Ramai D, Tai W, Rivera M, Facciorusso A, Tartaglia N, Pacilli M, Ambrosi A, Cotsoglou C, Sacco R. Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. Biomedicines 2021;9:184. [PMID: 33673113 DOI: 10.3390/biomedicines9020184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Dong J, Ren Y, Zhang T, Wang Z, Ling CC, Li GC, He F, Wang C, Wen B. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair. Oncol Rep 2018;39:912-20. [PMID: 29344644 DOI: 10.3892/or.2018.6217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
19 Xiao X, Liang J, Huang C, Li K, Xing F, Zhu W, Lin Z, Xu W, Wu G, Zhang J, Lin X, Tan Y, Cai J, Hu J, Chen X, Huang Y, Qin Z, Qiu P, Su X, Chen L, Lin Y, Zhang H, Yan G. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat Commun 2018;9:4342. [PMID: 30337542 DOI: 10.1038/s41467-018-06771-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
20 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 16.3] [Reference Citation Analysis]
21 Zhang Y, Wang H, Xiao H. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. Int J Mol Sci 2021;22:5016. [PMID: 34065108 DOI: 10.3390/ijms22095016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Lourenco LM, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR. Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. J Clin Invest 2020;130:258-71. [PMID: 31581151 DOI: 10.1172/JCI127483] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
23 Wang G, Guo S, Zhang W, Li Z, Xu J, Li D, Wang Y, Zhan Q. A Comprehensive Analysis of Alterations in DNA Damage Repair Pathways Reveals a Potential Way to Enhance the Radio-Sensitivity of Esophageal Squamous Cell Cancer. Front Oncol 2020;10:575711. [PMID: 33178606 DOI: 10.3389/fonc.2020.575711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Dong J, Zhang T, Ren Y, Wang Z, Ling CC, He F, Li GC, Wang C, Wen B. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks. Oncotarget 2017;8:22662-73. [PMID: 28186989 DOI: 10.18632/oncotarget.15153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
25 Zhao Q, Wongpoomchai R, Chariyakornkul A, Xiao Z, Pilapong C. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics. Front Oncol 2021;11:740484. [PMID: 34745960 DOI: 10.3389/fonc.2021.740484] [Reference Citation Analysis]
26 Dungl DA, Maginn EN, Stronach EA. Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy. Front Oncol 2015;5:240. [PMID: 26579492 DOI: 10.3389/fonc.2015.00240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
27 Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FE, Allan JM, Pollard JR, Curtin NJ. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 2015;6:32396-409. [PMID: 26486089 DOI: 10.18632/oncotarget.6136] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
28 Wang M, Chen S, Ao D. Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm (2020) 2021;2:654-91. [PMID: 34977872 DOI: 10.1002/mco2.103] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zicari S, Sharma AL, Sahu G, Dubrovsky L, Sun L, Yue H, Jada T, Ochem A, Simon G, Bukrinsky M, Tyagi M. DNA dependent protein kinase (DNA-PK) enhances HIV transcription by promoting RNA polymerase II activity and recruitment of transcription machinery at HIV LTR. Oncotarget 2020;11:699-726. [PMID: 32133046 DOI: 10.18632/oncotarget.27487] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Sishc BJ, Davis AJ. The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers (Basel) 2017;9:E81. [PMID: 28684677 DOI: 10.3390/cancers9070081] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 10.6] [Reference Citation Analysis]
31 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Timme CR, Rath BH, O'Neill JW, Camphausen K, Tofilon PJ. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts. Mol Cancer Ther 2018;17:1207-16. [PMID: 29549168 DOI: 10.1158/1535-7163.MCT-17-1267] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
33 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
34 Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget 2017;8:113418-30. [PMID: 29371919 DOI: 10.18632/oncotarget.21300] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
35 Wang H, Chen X, Calvisi DF. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opin Ther Targets 2021;25:645-58. [PMID: 34477018 DOI: 10.1080/14728222.2021.1976142] [Reference Citation Analysis]
36 Hausmann M, Ilić N, Pilarczyk G, Lee JH, Logeswaran A, Borroni AP, Krufczik M, Theda F, Waltrich N, Bestvater F, Hildenbrand G, Cremer C, Blank M. Challenges for Super-Resolution Localization Microscopy and Biomolecular Fluorescent Nano-Probing in Cancer Research. Int J Mol Sci 2017;18:E2066. [PMID: 28956810 DOI: 10.3390/ijms18102066] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
37 Cheng L, Liu YY, Lu PH, Peng Y, Yuan Q, Gu XS, Jin Y, Chen MB, Bai XM. Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells. Oncotarget 2017;8:28385-94. [PMID: 28415690 DOI: 10.18632/oncotarget.16073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Man SM, Jenkins BJ. Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer 2022. [PMID: 35355007 DOI: 10.1038/s41568-022-00462-5] [Reference Citation Analysis]
39 Zhang Y, Yang WK, Wen GM, Tang H, Wu CA, Wu YX, Jing ZL, Tang MS, Liu GL, Li DZ, Li YH, Deng YJ. High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival. Mol Genet Genomic Med 2019;7:e908. [PMID: 31513357 DOI: 10.1002/mgg3.908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
40 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]